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response to aspirin as assessed by arachidonic acid-induced aggregation or in
response to clopidogrel as assessed by ADP-induced aggregation or activa-
tion markers. There was a trend observed for lower reduction in PAC-1
binding after administration of clopidogrel in PLA2 carriers (P  .065).
Comment: This study reached somewhat different conclusions than
others on this subject in that it did not find an association between polymor-
phism of the PL (A1/A2) gene and aspirin insensitivity. Others have found
such a correlation (Br J Hemotol 2000;110:965-7). The authors studied
slightly different patients and used slightly different assays than previous
studies. This may be part of the explanation for their findings. It is also
possible various drug interactions, platelet turnover, drug absorption, and
individual metabolism also can affect aspirin and clopidogrel sensitivity.
Has evidence changed practice? Appropriateness of carotid endarterec-
tomy after the clinical trials
Halm EA, Tuhrim S, Wang JJ, et al. Neurology 2007;68:187-94.
Conclusion: The randomized trials of carotid endarterectomy (CEA)
have resulted in a reduction in the proportion of patients undergoing CEA
for inappropriate reasons.
Summary: The stimulus for the random trials of CEA was, in part, a
publication from the RANDCorporation indicating a high level of inappro-
priate performance of CEA. In the current report, the authors sought to
assess whether the random trials of CEA changed the level of inappropriate
surgery. This was a patient-based cohort study of all CEAs performed on
elderly patients from January 1988 through June 1999 in New York. Data
were extracted from charts to assess appropriateness of surgery and clinical
indications. A list of 1557 indications for CEA was developed using RAND
appropriateness methods. In addition to indications for surgery, deaths and
strokes within 30 days were determined.
There were 9588 patients in the study. Mean age was 74.6 years. The
level of carotid stenosis was 70% to 99% in 93.6% of patients. Of these, 72.3%
underwent CEA for asymptomatic stenosis. Other indications for operation
were stroke in 9.1% and transient ischemic attack in 18.6%. Based on
pre-established criteria, 87.1% of CEAs were done for appropriate reasons,
4.3% for uncertain reasons, and 8.6% for inappropriate reasons. This was
compared with 32% of CEAs performed for inappropriate reasons before the
publication of the random trials of CEA (P .0001). Of the CEAs classified
as inappropriate, the most common reason was high comorbidity in an
asymptomatic patient (62.2%), CEA after a major stroke (14.2%), or CEA
for minimal stenosis (10.5%). When asymptomatic patients were operated
on and had high comorbidity, the risk of death or stroke more than doubled
compared with those with low or standard levels of comorbidities (7.13% vs
2.69%, P  .0001).
Comment: The article indicates that surgeons pay attention to good
scientific evidence and incorporate that evidence into their practice. Our
European colleagues, however, must be amazed at the high proportion of
CEAs performed for asymptomatic stenosis in the United States. Given that
there is a low therapeutic margin for carotid intervention for asymptomatic
stenosis, it is difficult to understand why a high-risk asymptomatic patient
should undergo any type of carotid intervention.
Long-term low-molecular-weight heparin verses usual care in proxi-
mal-vein thrombosis patients with cancer
Hull RD, Pineo GF, Brant RF and the LITE Trial Investigators. Am J Med
2006;119:1062-72.
Conclusion: In patients with cancer and proximal venous thrombosis,
low-molecular-weight heparin (LMWH) prevents recurrent venous throm-
boembolism (VTE) more effectively than warfarin therapy.
Summary: Recurrent VTE is more common in patients with cancer
than noncancer patients. There also appears to be a reduction in cancer
mortality in patients with VTE and cancer when treated with LMWH. In
addition, it appears vitamin K antagonists are associated with higher rates of
bleeding in secondary prevention of VTE in patients with cancer compared
with those patients treated with long-term LMWH. Other studies have also
suggested LMWH reduces VTE recurrence in patients with cancer (N Engl
J Med 2003;349:146-53). This trial evaluated LMWH vs vitamin K antag-
onist therapy for prevention of recurrent of VTE in cancer patients with
proximal venous thrombosis.
Patients in this multicenter, randomized, open-label clinical trial had
acute symptomatic proximal vein thrombosis and cancer. Patients were
randomized to long-term tinzaparin subcutaneously once daily vs usual care
long-term vitamin K antagonist therapy. Treatment was for 3 months.
Outcomes were assessed at 3 and 12 months. Recurrent VTE was diagnosed
by ultrasound imaging when there was a noncompressible venous segment
that previously was compressible. Recurrent VTE was diagnosed by venog-
raphy when there was a luminal filling defect not present on a baseline
venogram. Pulmonary embolism was confirmed by high probability ventila-
tion perfusion lung scans, pulmonary computed tomography scanning,
pulmonary angiography, or findings of pulmonary embolism at autopsy.
Patients were also assessed for both major and minor bleeding.
There were 200 patients randomized: 100 received tinzaparin and 100
received the usual vitamin K antagonist care. At 12 months, there was a 16%
incidence of recurrent VTE in the patients treated with vitamin K antago-
nists. There was a 7% recurrence of VTE in patients treated with LMWH (P
 .044; risk ratio  0.44; absolute difference –9.0; 95% confidence interval
[CI] –21.7 to –0.7). Bleeding was largely minor and occurred in 24 patients
receiving vitamin K antagonists and 27 patients receiving tinzaparin therapy
(absolute difference, –3.0; 95% CI, –9.l to 15.1). In those patients who had
no additional risk factors for bleeding, there were no major bleeding
episodes in the tinzaparin-treated patients (0/51) and only one incidence of
major bleeding in the patients receiving vitamin K antagonists (1/48).
There was a 47% mortality rate in each group at 1 year, with most of the
deaths secondary to cancer.
Comment: This article failed to confirm a cancer-related death survival
benefit in patients with cancer and proximal venous thrombosis treated with
LMWH.However, the patients in this study had advanced cancer, and many
had advanced metastatic disease. Previous studies suggested survival benefit
occurs only in those without metastatic disease (J Clin Oncol 2005;23:2123-
9). Nevertheless, patients with advanced cancer and proximal venous throm-
bosis may have improved quality of life through LMWH. Certainly, the lack
of need for laboratory monitoring, minimal bleeding risk, and decreased
recurrence of VTE would logically appear to improve quality of life. How-
ever, these patients are deteriorating from multiple reasons that may also
impair quality of life, and unfortunately, the authors did not include quality-
of-life assessment as part of their protocol.
Subintimal angioplasty of supra- and infrageniculate arteries
Aarts F, Blankensteijn JD, van der Vliet JA, et al. Ann Vasc Surg 2006;20:
620-4.
Conclusion: In this study, subintimal angioplasty provided only mod-
est technical and clinical success.
Summary: This was a single-center retrospective review of subintimal
angioplasty performed for chronic limb ischemia. The procedures were
performed betweenOctober 2002 andDecember 2004. Data were analyzed
for patient demographics, technical and clinical success, limb salvage, and
comorbidities.
There were 39 subintimal angioplasties performed in 37 patients.
Median age was 73 years, and approximately two thirds were men and one
third were women. Median follow-up was 9 months. Mortality at 30 days
was 8%. All-cause mortality at 24 months was 33%. Subintimal angioplasty
was limited to the superficial femoral artery in 23 cases (59%). In nine limbs
(23%), both the superficial femoral and popliteal/crural vessels were treated,
with the popliteal artery alone treated in three limbs, and crural arteries alone
treated in four limbs.
Initial technical success was 67%. Clinical success was 49%. Complica-
tions occurred in 11 patients (28%). Three complications were major and
included two acute arterial occlusions and one retroperitoneal hematoma.
An additional 24 surgical interventions were performed after the initial
angioplasty procedure, of which 12 were major amputations. Amputation-
free survival was 69% at 12 months (95% confidence interval 52% to 85%).
Comment: This obviously was a difficult group of patients with a high
amputation rate and a poor survival rate. Success rates reported in this study
for subintimal angioplasty are somewhat lower than those reported else-
where. Subintimal angioplasty is a technically demanding procedure. It may
be the authors were still on the learning curve. However, I suspect the results
reported here are what most would achieve applying this procedure to a
similar difficult cohort of patients.
The novel phosphodiesterase inhibitor NM-702 improves
claudication-limited exercise performance in patients with periph-
eral arterial disease
Brass EP, Anthony R, Cobb FR, et al. J Am Coll Cardiol 2006;48:2539-45.
Conclusion: In patients with claudication, use of NM-702 for 24
weeks is associated with improvements of ambulatory-based exercise perfor-
mance and laboratory-based exercise performance.
Summary: The authors tested the ability of NM-702 to improve
symptoms of intermittent claudication and exercise performance. NM-
702 is a phosphodiesterase inhibitor, as well as a thromboxane A2
synthase. This was a placebo-controlled, double-blind, randomized mul-
ticenter trial. Patients received 24 weeks of twice-daily treatment with 4
mg (n  126) or 8 mg of NM-702 (n  130), or placebo (n  130).
Compared with placebo, after 24 weeks of treatment with 8 mg of
NM-702, there was a significant increase in peak walking time with
graded treadmill exercise. In the placebo group, peak walking time
increased by 17.1%  49.0%. In the 4-mg NM-702 group, peak walking
time increased 22.1%  60.1%. In the 8-mg NM-702 group, peak
walking time increased 28.1%  50.5%. At 24 weeks, the 8-mg dose of
NM-702 was associated with significant improvements in treadmill-
walking claudication onset time compared with placebo. NM-702 also
clearly improved the physical component in physical functioning scores
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